Skip to main content

Table 2 The distribution of outcomes in the comparison cohorts

From: Cardiovascular risks and bleeding with non-vitamin K antagonist oral anticoagulant versus warfarin in patients with type 2 diabetes: a tapered matching cohort study

  Unmatched cohorts Cohorts after coarsened exact matching
Incident NOAC users (N = 862) Incident warfarin users (N = 626) Incident NOAC users (N = 582) Incident warfarin users (N = 486)
Hospitalisation mainly due to CVD, n (%) 190 (22.0) 63 (10.1) 91 (17.2) 44 (9.1)
Hospitalisation mainly due to bleeding, n (%) 50 (5.8) 33 (5.3) 25 (4.7) 18 (3.7)
Re-hospitalisation mainly due to CVD, n (%) 70 (8.1) 15 (2.4) 37 (7.0) 8 (1.7)
  1. CVD indicates cardiovascular diseases